DRUG · COUNSELLING NOTES
Lanadelumab
TAKHZYRO
Updated
New prescription
indication: _____. SC q2 wks, rotate sites; not for acute attacks; warned on allergies; serious/common AEs: site reactions, hypersensitivity, dizziness; non-pharm: avoid triggers, trigger diary.
Refill prescription
refilled, adherence discussed, no SEs were reported
Dose change
Dose change discussed. new dose reviewed; SC q2 wks, rotate sites; not for acute attacks; warned on allergies; serious/common AEs: site reactions, hypersensitivity, dizziness; non-pharm: avoid triggers, trigger diary.